Press releases

Receive e-mail alerts

Internal link ProQR to Present Clinical and Preclinical Progress from AX-0810 and AX-0811 at Upcoming Conferences
October 28, 2026 at 12:00 PM UTC
Internal link ProQR Announces Appointment of Chris Hart as Chief Data and AI Officer and Thomas Wolf to join the Board of Directors as Strategic AI Advisor
September 23, 2026 at 12:00 PM UTC
Internal link ProQR Announces First Participant Dosed in Phase 1 Study of AX-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026
September 09, 2026 at 12:00 PM UTC
Internal link ProQR to Participate in Upcoming Investor Conferences in September 2026
September 02, 2026 at 12:00 PM UTC
Internal link ProQR Announces Second Quarter 2026 Operating and Financial Results
August 13, 2026 at 11:00 AM UTC
Internal link ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement
June 25, 2026 at 10:35 AM UTC
Internal link ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform
June 25, 2026 at 10:25 AM UTC
Internal link ProQR Announces First Quarter 2026 Operating and Financial Results
May 12, 2026 at 11:00 AM UTC
Internal link ProQR Announces Multiple Upcoming Scientific Conference Presentations Highlighting the Breadth of its Axiomer™ RNA Editing Platform
May 11, 2026 at 12:00 PM UTC
Internal link ProQR Announces Annual General Meeting of Shareholders to be Held June 2, 2026
May 04, 2026 at 12:00 PM UTC
Internal link ProQR Announces Nomination of Dr. Lykke Hinsch Gylvin to its Board of Directors
April 30, 2026 at 12:00 PM UTC
Internal link ProQR Highlights Pipeline Expansion and Multiple Upcoming Clinical Catalysts at Investor and Analyst Event
April 08, 2026 at 08:00 PM UTC
Internal link ProQR Announces Partnership with Ginkgo Bioworks and Formation of AI Advisory Board
April 08, 2026 at 12:00 PM UTC
Internal link ProQR to Host Virtual Investor and Analyst Event Highlighting Pipeline on April 8, 2026
March 25, 2026 at 12:00 PM UTC
Internal link ProQR Announces Year End 2025 Operating and Financial Results
March 12, 2026 at 11:00 AM UTC
Internal link ProQR Announces Webcast of Presentation at the 2026 Citizens Life Sciences Conference
March 03, 2026 at 09:30 PM UTC
Internal link ProQR Announces Planned Changes to Board Composition
February 09, 2026 at 01:00 PM UTC
Internal link ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK Data, Development Candidate Selections, and 2026 Outlook
January 08, 2026 at 01:00 PM UTC
Internal link ProQR Announces Results for the Third Quarter of 2016
November 14, 2016 at 12:00 PM UTC
Internal link ProQR Announces that QR-010 Meets the Primary Endpoint in a Proof of Concept Study of Homozygous F508del Cystic Fibrosis Patients
October 27, 2016 at 11:00 AM UTC
Internal link ProQR Announces Clinical Data Presentations and Investor & Analyst Event at NACFC
September 27, 2016 at 11:00 AM UTC
Internal link ProQR to Present at Scientific and Investor Conferences in September
September 06, 2016 at 11:00 AM UTC
Internal link ProQR Announces Results for the Second Quarter of 2016
August 17, 2016 at 11:00 AM UTC
Internal link ProQR Receives Fast Track Designation from FDA for QR-010 for Cystic Fibrosis
July 19, 2016 at 11:00 AM UTC
Internal link ProQR to Release Topline Data from Proof of Concept Study of QR-010 in Cystic Fibrosis Patients at NACFC
June 21, 2016 at 01:00 PM UTC

Press releases

Internal link ProQR to Present Clinical and Preclinical Progress from AX-0810 and AX-0811 at Upcoming Conferences

Internal link ProQR Announces Appointment of Chris Hart as Chief Data and AI Officer and Thomas Wolf to join the Board of Directors as Strategic AI Advisor

Internal link ProQR Announces First Participant Dosed in Phase 1 Study of AX-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026

Internal link ProQR to Participate in Upcoming Investor Conferences in September 2026

Internal link ProQR Announces Second Quarter 2026 Operating and Financial Results

Internal link ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement

Internal link ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform

Internal link ProQR Announces First Quarter 2026 Operating and Financial Results

Internal link ProQR Announces Multiple Upcoming Scientific Conference Presentations Highlighting the Breadth of its Axiomer™ RNA Editing Platform

Internal link ProQR Announces Annual General Meeting of Shareholders to be Held June 2, 2026

Internal link ProQR Announces Nomination of Dr. Lykke Hinsch Gylvin to its Board of Directors

Internal link ProQR Highlights Pipeline Expansion and Multiple Upcoming Clinical Catalysts at Investor and Analyst Event

Internal link ProQR Announces Partnership with Ginkgo Bioworks and Formation of AI Advisory Board

Internal link ProQR to Host Virtual Investor and Analyst Event Highlighting Pipeline on April 8, 2026

Internal link ProQR Announces Year End 2025 Operating and Financial Results

Internal link ProQR Announces Webcast of Presentation at the 2026 Citizens Life Sciences Conference

Internal link ProQR Announces Planned Changes to Board Composition

Internal link ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK Data, Development Candidate Selections, and 2026 Outlook

Internal link ProQR Announces Results for the Third Quarter of 2016

Internal link ProQR Announces that QR-010 Meets the Primary Endpoint in a Proof of Concept Study of Homozygous F508del Cystic Fibrosis Patients

Internal link ProQR Announces Clinical Data Presentations and Investor & Analyst Event at NACFC

Internal link ProQR to Present at Scientific and Investor Conferences in September

Internal link ProQR Announces Results for the Second Quarter of 2016

Internal link ProQR Receives Fast Track Designation from FDA for QR-010 for Cystic Fibrosis

Internal link ProQR to Release Topline Data from Proof of Concept Study of QR-010 in Cystic Fibrosis Patients at NACFC